The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Pharmacological inhibitors of glycogen synthase kinase 3
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Specificity and mechanism of action of some commonly used protein kinase inhibitors
DAVIES, S. P., REDDY, H., CAIVANO, M., & COHEN, P. (2000) · Biochemical Journal · doi:10.1042/bj3510095 · Cited by 3,132
A molecular mechanism for the effect of lithium on development.
Klein, P. S., & Melton, D. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8455 · Cited by 2,301
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186
Sato, N., Meijer, L., Skaltsounis, L., Greengard, P., & Brivanlou, A. H. (2004) · Nature Medicine · doi:10.1038/nm979 · Cited by 2,109
Self-citationGSK-3: tricks of the trade for a multi-tasking kinase
Doble, B. W., & Woodgett, J. R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00384 · Cited by 2,084
The glamour and gloom of glycogen synthase kinase-3
Jope, R. S., & Johnson, G. V. W. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2003.12.004 · Cited by 1,517
GSK3 takes centre stage more than 20 years after its discovery
FRAME, S., & COHEN, P. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3590001 · Cited by 1,433
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369 · cited 6×
“However, because many GSK-3 inhibitors also affect CDKs (Table 1) [33], control experiments should be carried out using CDK inhibitors that do not target GSK-3 (such as roscovitine and purvalanol)[ 29 ].Insomecircumstances,CDK5‐GSK-3 dual specificity could be an advantage, as illustrated later.”
BackgroundInfluentialProtein Kinase Inhibitors: Insights into Drug Design from Structure
Noble, M. E. M., Endicott, J. A., & Johnson, L. N. (2004) · Science · doi:10.1126/science.1095920 · Cited by 1,198
Cited by
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells
Gattinoni, L., Zhong, X.-S., Palmer, D. C., Ji, Y., Hinrichs, C. S., Yu, Z., Wrzesinski, C., Boni, A., Cassard, L., Garvin, L. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1982 · Cited by 1,031
Rada, P., Rojo, A. I., Chowdhry, S., McMahon, M., Hayes, J. D., & Cuadrado, A. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01204-10 · Cited by 759
Differentiation and Persistence of Memory CD8+ T Cells Depend on T Cell Factor 1
Zhou, X., Yu, S., Zhao, D.-M., Harty, J. T., Badovinac, V. P., & Xue, H.-H. (2010) · Immunity · doi:10.1016/j.immuni.2010.08.002 · Cited by 688
Gong, C.-X., & Iqbal, K. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708785909111 · Cited by 644
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Samuel, M. S., Lopez, J. I., McGhee, E. J., Croft, D. R., Strachan, D., Timpson, P., Munro, J., Schröder, E., Zhou, J., Brunton, V. G., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.008 · Cited by 541
Glycogen synthase kinase 3: more than a namesake
Rayasam, G. V., Tulasi, V. K., Sodhi, R., Davis, J. A., & Ray, A. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00085.x · Cited by 483
Doble, B. W., Patel, S., Wood, G. A., Kockeritz, L. K., & Woodgett, J. R. (2007) · Developmental Cell · doi:10.1016/j.devcel.2007.04.001 · Cited by 448
Therapeutic potential of mood stabilizers lithium and valproic acid:Beyond bipolar disorder
Chiu, C.-T., Wang, Z., Hunsberger, J. G., & Chuang, D.-M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005512 · Cited by 404
A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy
Tolosa, E., Litvan, I., Höglinger, G. U., Burn, D., Lees, A., Andrés, M. V., Gómez‐Carrillo, B., León, T., del Ser, T., & for the TAUROS Investigators (2014) · Movement Disorders · doi:10.1002/mds.25824 · Cited by 320
Is Glycogen Synthase Kinase-3 a Central Modulator in Mood Regulation?
Li, X., & Jope, R. S. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.105 · Cited by 294
Ruthenium complexes can target determinants of tumour malignancy
Bergamo, A., & Sava, G. (2007) · Dalton Transactions · doi:10.1039/b617769g · Cited by 291
A Chaperone-Dependent GSK3β Transitional Intermediate Mediates Activation-Loop Autophosphorylation
Lochhead, P. A., Kinstrie, R., Sibbet, G., Rawjee, T., Morrice, N., & Cleghon, V. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.10.009 · Cited by 283
Shakoori, A., Ougolkov, A., Yu, Z. W., Zhang, B., Modarressi, M. H., Billadeau, D. D., Mai, M., Takahashi, Y., & Minamoto, T. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.07.041 · Cited by 272
De Rybel, B., Audenaert, D., Vert, G., Rozhon, W., Mayerhofer, J., Peelman, F., Coutuer, S., Denayer, T., Jansen, L., Nguyen, L., et al. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.04.008 · Cited by 271
Wnt Proteins Promote Bone Regeneration
Minear, S., Leucht, P., Jiang, J., Liu, B., Zeng, A., Fuerer, C., Nusse, R., & Helms, J. A. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000231 · Cited by 266
Menendez, L., Yatskievych, T. A., Antin, P. B., & Dalton, S. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113746108 · Cited by 264
Mica, Y., Lee, G., Chambers, S. M., Tomishima, M. J., & Studer, L. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.03.025 · Cited by 257
Röttinger, E., Dahlin, P., & Martindale, M. Q. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1003164 · Cited by 140
Roscovitine-Derived, Dual-Specificity Inhibitors of Cyclin-Dependent Kinases and Casein Kinases 1
Oumata, N., Bettayeb, K., Ferandin, Y., Demange, L., Lopez-Giral, A., Goddard, M.-L., Myrianthopoulos, V., Mikros, E., Flajolet, M., Greengard, P., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800109e · Cited by 139
Self-citationWu, X., Yang, Z., Zou, J., Gao, H., Shao, Z., Li, C., & Lei, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02179-x · Cited by 88
Hsu, P.-H., Lin, Y.-T., Chung, Y.-H., Lin, K.-J., Yang, L.-Y., Yen, T.-C., & Liu, H.-L. (2018) · Scientific Reports · doi:10.1038/s41598-018-31071-8 · Cited by 70
Wei, J., Wang, J., Zhang, J., Yang, J., Wang, G., & Wang, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114301 · Cited by 42
Hematopoietic stem cells, hematopoiesis and disease: lessons from the zebrafish model
Martin, C. S., Moriyama, A., & Zon, L. I. (2011) · Genome Medicine · doi:10.1186/gm299 · Cited by 29
Elucidation of the GSK3α Structure Informs the Design of Novel, Paralog-Selective Inhibitors
Amaral, B., Capacci, A., Anderson, T., Tezer, C., Bajrami, B., Lulla, M., Lucas, B., Chodaparambil, J. V., Marcotte, D., Kumar, P. R., et al. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00476 · Cited by 22
Bioactive Compounds and Diabetes Mellitus: Prospects and Future Challenges
Rahman, M. M., Islam, M. R., Rabbi, F., Islam, M. T., Sultana, S., Ahmed, M., Sehgal, A., Singh, S., Sharma, N., & Behl, T. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220412090808 · Cited by 13
Metadata
- Authors
- MEIJER, L., FLAJOLET, M., & GREENGARD, P.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2004-09
- Volume
- 25
- Issue
- 9
- Pages
- 471-480
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W2034595626
- Cited by
- 584
- References
- 87
- FWCI
- 12.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.